» Authors » Cindy Luongo

Cindy Luongo

Explore the profile of Cindy Luongo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 946
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Park H, Matsuoka Y, Santos C, Luongo C, Liu X, Yang L, et al.
bioRxiv . 2024 Oct; PMID: 39372768
The continuous emergence of new SARS-CoV-2 variants requires that COVID vaccines be updated to match circulating strains. We generated B/HPIV3-vectored vaccines expressing 6P-stabilized S protein of the ancestral, B.1.617.2/Delta, or...
2.
Kaiser J, Nelson C, Liu X, Park H, Matsuoka Y, Luongo C, et al.
Nat Commun . 2024 Apr; 15(1):3553. PMID: 38670948
Immunization via the respiratory route is predicted to increase the effectiveness of a SARS-CoV-2 vaccine. Here, we evaluate the immunogenicity and protective efficacy of one or two doses of a...
3.
Alamares-Sapuay J, Kishko M, Lai C, Parrington M, Delagrave S, Herbert R, et al.
PLoS One . 2024 Apr; 19(4):e0301773. PMID: 38593167
Respiratory syncytial virus (RSV) is the leading viral cause of bronchiolitis and pneumonia in infants and toddlers, but there currently is no licensed pediatric vaccine. A leading vaccine candidate that...
4.
Kaiser J, Liu X, Luongo C, Matsuoka Y, Santos C, Yang L, et al.
iScience . 2023 Dec; 26(12):108490. PMID: 38144450
Next-generation SARS-CoV-2 vaccines are needed that induce systemic and mucosal immunity. Murine pneumonia virus (MPV), a murine homolog of respiratory syncytial virus, is attenuated by host-range restriction in nonhuman primates...
5.
Buchholz U, Kaiser J, Nelson C, Liu X, Park H, Matsuoka Y, et al.
Res Sq . 2023 Oct; PMID: 37790295
Immunization via the respiratory route is predicted to increase the effectiveness of a SARS-CoV-2 vaccine. We evaluated the immunogenicity and protective efficacy of one or two doses of a live-attenuated...
6.
Karron R, Luongo C, Woods S, Oliva J, Collins P, Buchholz U
J Infect Dis . 2023 Jul; 229(2):346-354. PMID: 37493269
Background: Respiratory syncytial virus (RSV) is the leading cause of pediatric lower respiratory illness (LRI) and a vaccine for immunization of children is needed. RSV/6120/ΔNS2/1030s is a cDNA-derived live-vaccine candidate...
7.
Liu X, Park H, Matsuoka Y, Santos C, Yang L, Luongo C, et al.
PLoS Pathog . 2023 Jun; 19(6):e1011057. PMID: 37352333
The pediatric live-attenuated bovine/human parainfluenza virus type 3 (B/HPIV3)-vectored vaccine expressing the prefusion-stabilized SARS-CoV-2 spike (S) protein (B/HPIV3/S-2P) was previously evaluated in vitro and in hamsters. To improve its immunogenicity,...
8.
Liu X, Park H, Matsuoka Y, Santos C, Yang L, Luongo C, et al.
bioRxiv . 2022 Dec; PMID: 36561185
Author Summary: SARS-CoV-2 infects and causes disease in all age groups. While injectable SARS-CoV-2 vaccines are effective against severe COVID-19, they do not fully prevent SARS-CoV-2 replication and transmission. This...
9.
Le Nouen C, Nelson C, Liu X, Park H, Matsuoka Y, Luongo C, et al.
Cell . 2022 Nov; 185(25):4811-4825.e17. PMID: 36423629
Pediatric SARS-CoV-2 vaccines are needed that elicit immunity directly in the airways as well as systemically. Building on pediatric parainfluenza virus vaccines in clinical development, we generated a live-attenuated parainfluenza-virus-vectored...
10.
Park H, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, et al.
NPJ Vaccines . 2022 Jun; 7(1):72. PMID: 35764659
Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are administered parenterally and appear to be more protective in the lower versus the upper respiratory tract. Vaccines are needed...